pharmaphorum June 10, 2024
Phil Taylor

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with regulatory authorities.

The trial of mRNA-1083 met its objectives, stimulating higher immune responses against influenza and SARS-CoV-2 than the licensed flu and COVID vaccines used as comparators in the trial, which involved adults 50 years and older.

The readout puts Moderna in pole position among combination vaccine developers with the potential for approval in late 2025 or 2026, depending on the outcome of the interactions with regulators, according to the company’s chief executive Stéphane Bancel.

“Combination vaccines have the potential to reduce the burden of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Roche partners with RNA editing biotech Ascidian
340B drug program spending up 19% + 6 other notes
Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
How Multi-Omics Is Empowering The Discovery Of Cancer Biomarkers

Share This Article